Article Text

Download PDFPDF
Response to: ‘Which B-cell subset should we target in lupus?’ by Ferraccioli and Houssiau
  1. Gururaj Arumugakani1,2,3,
  2. Edward M Vital1,2,
  3. Md Yuzaiful Md Yusof1,2,
  4. Dennis G McGonagle1,2,
  5. Paul Emery1,2
  1. 1Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds, Leeds, UK
  2. 2NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  3. 3Department of Clinical Immunology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  1. Correspondence to Dr Gururaj Arumugakani, Department of Clinical Immunology, St. James's University Hospital, Leeds LS9 7TF, UK; g.arumugakani{at}

Statistics from

We read with interest the editorial by Ferraccioli and Houssiau proposing the specific targeting of long-lived plasma cells (PCs) in human lupus nephritis (LN).1 The authors present a cogent summary of experiments showing that long-lived PCs alone are sufficient to induce murine LN, and that targeting of PCs in these models is successful. However, we believe that clinical experience with the treatment of human SLE indicates that plasmablasts and short-lived PCs, recently derived from autoreactive B cells, are more important in the …

View Full Text


  • Competing interests Paul Emery and Edward M Vital have received honoraria and research grant support from Roche.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Electronic pages
    Gianfranco Ferraccioli Frédéric A Houssiau